Osprey Pharmaceuticals Limited Announces Issuance of 3 U.S. Patents
Patents Broadly Protect Core Technology Behind Chemokine-based Therapeutic Platform
Advertisement
Osprey Pharmaceuticals Limited, a privately held biotechnology company focused on treating chronic diseases through a family of first-in-class therapeutic proteins, announced that it has been granted three patents by the U.S. Patent Office. The patents protect the use of conjugated chemokines to selectively and systematically eliminate overactive leukocytes implicated in most chronic diseases, the core technology behind Osprey's Leukocyte Population Modulator (LPM) platform.
"These patents confirm our unique position to commercialize the only therapeutic approach capable of addressing the in-common biological hallmark of many known diseases: over-expression of chemokines and chemokine receptors by overabundant and overactive leukocytes," said John McDonald, PhD, co-founder of Osprey Pharmaceuticals. "The timing of the patent issuance comes at an important stage of the company's development, as we move our first LPM for the treatment of chronic kidney disease into the clinic later this year."
The specific patents issued are:
- US Patent 7,157,418 entitled "Methods and Compositions for Treating Secondary Tissue Damage and Other Inflammatory Conditions and Disorders"
- US Patent 7,166,702 entitled "Cytotoxic Conjugates Comprising a Chemokine Receptor Targeting Agent"
- US Patent 7,192,736 entitled "Nucleic Acid Molecules Encoding Cytotoxic Conjugates That Contain a Chemokine Receptor Targeting Agent"
Other news from the department research and development
